KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Current Assets (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Current Assets data on record, last reported at $1.1 billion in Q4 2025.

  • For Q4 2025, Current Assets rose 13.19% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, up 13.19%, while the annual FY2025 figure was $1.1 billion, 13.19% up from the prior year.
  • Current Assets reached $1.1 billion in Q4 2025 per ACAD's latest filing, down from $1.1 billion in the prior quarter.
  • Across five years, Current Assets topped out at $1.1 billion in Q3 2025 and bottomed at $492.6 million in Q2 2023.
  • Average Current Assets over 5 years is $694.7 million, with a median of $643.3 million recorded in 2021.
  • Peak YoY movement for Current Assets: decreased 19.55% in 2022, then skyrocketed 57.92% in 2024.
  • A 5-year view of Current Assets shows it stood at $617.8 million in 2021, then dropped by 17.79% to $507.9 million in 2022, then rose by 21.3% to $616.1 million in 2023, then skyrocketed by 52.29% to $938.3 million in 2024, then increased by 13.19% to $1.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $1.1 billion in Q4 2025, $1.1 billion in Q3 2025, and $960.6 million in Q2 2025.